Novartis says its Soliris add-on might be able to replace the Alexion drug altogether. But is it too late?
Novartis says one of its top emerging drugs spotlighted by Vas Narasimhan has come through in a Phase II trial for paroxysmal nocturnal hemoglobinuria, burnishing its prospect as an add-on — or even alternative — to Alexion’s Soliris.
Going after the alternative complement pathway, the pharma giant sees oral administration as one of LNP023’s key attractions — although analysts say it’s too late to make much of a difference in this particular rare blood disorder.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 150,300+ biopharma pros reading Endpoints daily — and it's free.